TY - T1的阿奇霉素的随机对照试验,防止肺移植后慢性排斥反应JF -欧洲呼吸杂志》乔和J SP - 164 LP - 172欧元做- 10.1183/09031936.00068310六世- 37 - 1 AU - r . Vos盟B.M. Vanaudenaerde AU - S.E. Verleden盟S.I. De Vleeschauwer AU - A . Willems-Widyastuti盟D.E. Van Raemdonck AU - A . Schoonis盟盟T.S. Nawrot - l·J·杜邦盟通用Verleden Y1 - 2011/01/01 UR - //www.qdcxjkg.com/content/37/1/164.abstract N2 -阿奇霉素减少气道炎症,改善在1 s用力呼气量(FEV1)在慢性排斥反应或闭塞性细支气管炎综合征(BOS)后肺移植(第)。阿奇霉素预防可能防止BOS。阿奇霉素的双盲随机对照试验(n = 40)或安慰剂(n = 43),开始放电,每周进行三次2年,2005 - 2009年进行了鲁汶大学医院(比利时鲁汶)。主要终端BOS-free和整体生存2年在肝;二级终端是急性排斥、淋巴细胞性细支气管炎和肺炎,患病率pseudomonal气道殖民或gastro-oesophageal回流,并更改在残,气道和系统性炎症。病人发展BOS FEV1和非盲阿奇霉素的变化进行评估。BOS发生在患者接受阿奇霉素:12.5和44.2% (p = 0.0017)。BOS-free生存是更好的与阿奇霉素(风险比为0.27,95%可信区间0.092 - -0.816;p = 0.020)。总体存活率、急性排斥,淋巴细胞性细支气管炎,肺炎,组间可比性殖民化和回流。 Patients receiving azithromycin demonstrated better FEV1 (p = 0.028), and lower airway neutrophilia (p = 0.015) and systemic C-reactive protein levels (p = 0.050) over time. Open-label azithromycin for BOS improved FEV1 in 52.2% patients. No serious adverse events were noted. Azithromycin prophylaxis attenuates local and systemic inflammation, improves FEV1 and reduces BOS 2 yrs after LTx. ER -